Advanced Accelerator Applications (AAA), an international specialist in molecular nuclear medicine, has announced that Dr. Kapil Dhingra has joined the company board of directors as an independent non-executive director.
Stefano Buono, CEO of AAA, said, "Dhingra's guidance and perspective on clinical development, regulatory and commercial strategy will be of tremendous benefit as we advance our pipeline of product candidates and our lead product candidate, Lu-DOTATATE (Lutathera), currently in a pivotal phase III trial for the treatment of gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). Dhingra's recent experience serving on the board of Algeta, which had its key radiopharmaceutical product, Xofigo, approved in the U.S. and Europe last year for targeted internal radiotherapy for advanced prostate cancer, also will be extremely valuable."
Dhingra has over 25 years' experience in oncology clinical research and drug development, including nine years at Roche Pharmaceuticals, where he played a key role in the expansion of Roche Oncology. From 1999 to 2008 he served in positions of increasing responsibility at Roche, including vice president, head of Oncology Disease Biology Leadership Team and head of Oncology Clinical Development.
Previously, Dhingra worked in the oncology clinical development group at Eli Lilly. He also was a clinical instructor, assistant professor of Medicine at the University of TexasM.D. Anderson Cancer Center.